DNAY - Codex: Synthetic DNA/mRNA Instrument Developer Holds Impressive Upside In 2021

• Codex DNA, Inc. is a new focused synthetic biology company developing lab instruments, reagents, and associated products while providing various other services.
• Codex DNA's products include the BioXp™ system, a fully automated benchtop instrument for generating synthetic DNA/mRNA from DNA sequence; BioXp™ kits which contain all the necessary Gibson Assembly® reagents; and more.
• Codex is in a strong financial position with TTM (ended 2Q 2021) revenues of $8.8M, cash at 2Q 2021 of $124M, and a minimal TTM cash burn of -$20M.
• Codex is expected to witness impressive revenue growth for the period 2020-2025 reaching revenues of $110.5M by 2025 with a promising CAGR of +76%.
• In summary, the author projects Codex DNA, Inc. as a "buy" at a 1-2 year price target of $15.6/share (+54% upside).

For further details see: